The effects of oral zinc sulphate during radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer: a prospective, randomised, placebo-controlled study.
The purpose was to determine the effects of oral zinc sulphate along with radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer. Thirty patients with head and neck cancer were randomly assigned to receive either zinc sulphate capsules (including 50 mg zinc) (n = 15) or placebo (n = 15) three times a day, starting on the day of the first radiotherapy fraction and continuing throughout the scheduled radiotherapy course including weekends and 6 weeks after radiotherapy. The patients were treated with telecobalt radiation at conventional fractionation of 2 Gy/fraction and five fractions/ week in 20-35 fractions for a period of 4-7 weeks. Blood samples for biochemical parameters were collected after an overnight fast (12 h) before radiotherapy, the first day and 6 weeks after radiotherapy. In the placebo group, three patients were excluded. No difference was detected in any final measurement activities of erythrocyte anti-oxidant enzyme such as copper-zinc superoxide dismutase (Cu-Zn SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in the direct comparison between the zinc sulphate and the placebo group, except erythrocyte SOD activities measured the first day after radiotherapy (p < 0.03). In the respective measurement analysis of the groups in themselves, in the zinc sulphate group, while the statistical analysis for the activities of erythrocyte CAT and GSH-Px were significantly different (chi2 = 12.4, p < 0.05; chi2 = 8.9, p < 0.05, respectively) before radiotherapy, the first day and 6 weeks after radiotherapy, the activities of SOD did not differ (chi2 = 4.2, p > 0.05). In these three measurements, there was no statistical significance in the activities of enzymes in erythrocyte Cu-Zn SOD, CAT and GSH-Px in the placebo group. Before radiotherapy, plasma zinc levels were normal in 16 patients (59.2%) and were lower in 11 patients (40.8%) compared with laboratory levels. It would be worthwhile studying the effect of oral zinc sulphate supplements to improve the anti-oxidant enzyme activity in radiation-treated cancer patients, in the hope of reducing radiation-induced toxicity.
Ertekin
M V
MV
Department of Radiation Oncology, Atatürk University Medical Faculty, Erzurum, Turkey. mvertekin@hotmail.com
Koç
M
M
Karslioğlu
I
I
Sezen
O
O
Taysi
S
S
Bakan
N
N
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000528:radiation effects*; D002374:Catalase / Q000378:metabolism; D003131:Combined Modality Therapy; D005260:Female; D005979:Glutathione Peroxidase / Q000378:metabolism; D006258:Head and Neck Neoplasms / Q000201:enzymology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress; D011446:Prospective Studies; D011832:Radiation Injuries / Q000201:enzymology / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000378:metabolism; D016896:Treatment Outcome; D019287:Zinc Sulfate / Q000627:therapeutic use*
D000975:Antioxidants; D019287:Zinc Sulfate; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase